Vaxcyte, Inc.
PCVXNext catalyst
31-valent pneumococcal conjugate vaccine
Pneumococcal Vaccines
Get an email about PCVX's next catalysts
Track Vaxcyte (PCVX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 1 past
PCVX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.84 | FQ end Sep/2026 | Call: tbd
31-valent pneumococcal conjugate vaccine Phase 3 Est. Readout
Estimated primary completion for 31-valent pneumococcal conjugate vaccine trial (NCT07365826) in Pneumococcal Vaccines. Topline data typically follows completion by weeks to months.
SourceHow PCVX's past catalysts played out
Market Overview
Stock performance and key metrics
31 valent pneumococcal conjugate vaccine
Pneumococcal Vaccines
Seasonal Influenza Vaccine (SIV) (Flublok)
Pneumococcal Vaccines
PCV20
Pneumococcal Vaccines
31-valent pneumococcal conjugate vaccine
Pneumococcal Vaccines
the High-PFS dose VAX-31
Pneumococcal Vaccines
the mid dose VAX-31
Pneumococcal Vaccines
the low dose VAX-31
Pneumococcal Vaccines
the high dose VAX-31
Pneumococcal Vaccines
24 valent pneumococcal conjugate vaccine
Pneumococcal Vaccines
VAX-24
Pneumococcal Vaccines
24-Valent Pneumococcal Conjugate Vaccine
Pneumococcal Vaccines
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
31 valent pneumococcal conjugate vaccine | Phase 3 | Pneumococcal Vaccines | - | - |
Seasonal Influenza Vaccine (SIV) (Flublok) | Phase 3 | Pneumococcal Vaccines | - | - |
PCV20 | Phase 3 | Pneumococcal Vaccines | - | - |
31-valent pneumococcal conjugate vaccine | Phase 3 | Pneumococcal Vaccines | - | - |
the High-PFS dose VAX-31 | Phase 2 | Pneumococcal Vaccines | - | - |
the mid dose VAX-31 | Phase 2 | Pneumococcal Vaccines | - | - |
the low dose VAX-31 | Phase 2 | Pneumococcal Vaccines | - | - |
the high dose VAX-31 | Phase 2 | Pneumococcal Vaccines | - | - |
24 valent pneumococcal conjugate vaccine | Phase 2 | Pneumococcal Vaccines | - | - |
VAX-24 | Phase 2 | Pneumococcal Vaccines | - | - |
24-Valent Pneumococcal Conjugate Vaccine | Phase 2 | Pneumococcal Vaccines | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Vaxcyte, Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in Vaxcyte, Inc.'s (PCVX) pipeline across Phase 3, Phase 2. Its lead program is 31-valent pneumococcal conjugate vaccine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vaxcyte, Inc.'s next FDA catalyst?→
Vaxcyte, Inc.'s (PCVX) next tracked catalyst is a Phase 3 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PCVX biotech catalysts?→
Add PCVX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vaxcyte, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.